Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health reform update

This article was originally published in The Gray Sheet

Executive Summary

In a March 3 speech at the White House, President Obama urged congressional leaders to accept his health care reform proposal including his endorsement of a $20 billion excise tax on the device industry - and vote on it over the next several weeks using the budget reconciliation process. But there are enough wavering Democrats in the House to make success uncertain. Approval would begin with a House vote blessing the Dec. 24-passed Senate health care reform bill, legislation that does not include strong enough abortion restrictions for some conservative House Democrats and does not contain aggressive enough coverage provisions for some liberals. Then a "reconciliation bill" would incorporate some of the president's proposals from a Feb. 25 health care summit (1"The Gray Sheet" March 1, 2010). In a bid to win more bipartisan support for health reform, Obama penned a letter to congressional leaders March 2, asking them to tack on to the legislation some proposals from Republicans, though opposition from the latter camp remains strong

You may also be interested in...



Device Excise Tax Survives In Obama Health Reform Proposal

President Obama included a $20 billion excise tax on the device industry, similar to a provision passed by the House last November, in a health care reform proposal he issued in the lead-up to a Feb. 25 bipartisan summit

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel